

Box 5.3 Screen, Treat, Optimize and Prevent AIDS among children

Screen ^a	
TB	<ul style="list-style-type: none"> • Screen for TB using available screening tools as indicated^b • For those who screen positive, use the following diagnostic tests to confirm TB as applicable^c: <ul style="list-style-type: none"> – Rapid molecular diagnostic on (induced) sputum, stool, gastric aspirate or nasopharyngeal aspirate or other extrapulmonary samples if relevant – LF-LAM assay^d
Cryptococcal infection among adolescents	Serum or plasma or blood cryptococcal antigen screening followed by lumbar puncture if positive or symptomatic
Malnutrition	<ul style="list-style-type: none"> • Weight-for-height • Height-for-age • Mid-upper arm circumference among children 2–5 years old
Treat	
TB, severe pneumonia, severe bacterial infections, cryptococcal meningitis and severe acute malnutrition	In accordance with WHO guidelines
Optimize	
Rapid ART start	Preferably same-day but no later than seven days after diagnosis with optimal regimens ^e
ART counselling	In accordance with WHO guidelines
Prevent	
Bacterial infections and <i>P. jirovecii</i> pneumonia	Co-trimoxazole prophylaxis
TB	TB preventive treatment
Cryptococcal meningitis among adolescents	Fluconazole pre-emptive therapy if cryptococcal antigen positive or cryptococcal antigen unavailable
Vaccinations	<ul style="list-style-type: none"> • Pneumococcal vaccine • Human papillomavirus • Measles • BCG

^a Screening refers to screening and diagnostics throughout this publication.

^b For screening algorithms and screening tools, see *WHO consolidated guidelines on tuberculosis: module 1: prevention: tuberculosis preventive treatment (28)* and *WHO operational handbook on tuberculosis: module 1: prevention: tuberculosis preventive treatment (75)*. Screening and diagnosis of TB for adolescents is the same as for adults.

^c A negative test result does not exclude TB for children living with HIV for whom there is a strong clinical suspicion of TB.


^d *Package of care for children and adolescents with advanced HIV disease: stop AIDS: technical brief (76)*.

^e Unless TB or cryptococcal meningitis is diagnosed (77).



Fig. 5.1 Algorithm for providing a package of care for people with advanced HIV disease

- Any person who has signs of being seriously ill should be referred to the appropriate higher-level facility for management.
- A seriously ill adult is defined as having any of the following danger signs: respiratory rate ≥ 30 breaths per minute; heart rate ≥ 120 beats per minute; or unable to walk unaided. Other clinical condition, such as temperature $\geq 39^\circ\text{C}$ combined with other signs such as headache, can also be considered based on local epidemiology and clinical judgement. A seriously ill child is defined as having any of the following danger signs: lethargy or unconsciousness; convulsions; unable to drink or breastfeed; and repeated vomiting. Other clinical conditions such as temperature $\geq 39^\circ\text{C}$ and age-defined tachycardia and/or tachypnoea can be considered based on clinical judgement.
- Clear criteria for referral should be available. If the person is not seriously ill, the decision as to what interventions may be decentralized will be programmatic.
- For those hospitalized: mortality is highest in the first 48 hours after admission. Steps 1–4 should be completed as soon as possible on the same day as presentation. Based on clinical assessment: start TB and opportunistic infection therapies as soon as possible among those who are seriously ill. The availability of point-of-care diagnostics (CD4, cryptococcal antigen, LF-LAM and viral load) will support rapid diagnosis, including at decentralized sites.




ART: antiretroviral therapy; CSF: cerebrospinal fluid; TB, tuberculosis; LF-LAM: lateral flow urine lipoarabinomannan assay.

^a Everyone who is cryptococcal antigen positive and has headache or confusion should have a lumbar puncture.

^b In settings where test results are available quickly, testing for cryptococcal infection before TB infection would be more cost-effective.

Box 5.1 Summary of recommendations (2018)



Prevention and screening

Overarching principle

Screening for cryptococcal antigen is the optimal approach for guiding resources in a public health approach and is the preferred approach for identifying infection when managing people aged 10 years or older presenting with advanced HIV disease (25).

Recommendations

Screening for cryptococcal antigen followed by pre-emptive antifungal therapy (35)^a among cryptococcal antigen-positive people to prevent the development of invasive cryptococcal disease are recommended before initiating or reinitiating ART for adults and adolescents living with HIV who have a CD4 count <100 cells/mm³ (36)

(strong recommendation, moderate-certainty evidence).

This may be considered at a higher CD4 cell count threshold of <200 cells/mm³ (36)

(conditional recommendation, moderate-certainty evidence).

All people living with HIV with a positive cryptococcal antigen result on screening should be carefully evaluated for signs and symptoms of meningitis and undergo a lumbar puncture, if feasible, with CSF examination and India ink or CSF cryptococcal antigen assay to exclude active cryptococcal disease. India ink has low sensitivity, and a negative result on India ink should be confirmed by CSF cryptococcal antigen testing.

When cryptococcal antigen screening is not available, fluconazole primary prophylaxis should be given to adults and adolescents living with HIV who have a CD4 count <100 cells/mm³ (37)

(strong recommendation, moderate-certainty evidence).

This may be considered at a higher CD4 cell count threshold of <200 cells/mm³ (36)

(conditional recommendation, moderate-certainty evidence).

^aThe Southern African HIV Clinicians' Society recommends starting ART two weeks after starting fluconazole, and consideration is being given to starting ART immediately if lumbar puncture excludes cryptococcal meningitis among people who test positive for whole-blood cryptococcal antigen.

Table 5.4 Recommendations for the package of prophylaxis interventions for people with advanced HIV disease

Intervention	Indication to start			Indication to stop		
	Adults	Adolescents	Children	Adults	Adolescents	Children
Co-trimoxazole prophylaxis	<p>Severe or advanced HIV clinical disease (WHO clinical stage 3 or 4) and/or with a CD4 cell count <350 cells/mm³.</p> <p><i>Strong recommendation, moderate-certainty evidence</i></p> <p>Malaria and/or severe bacterial infections highly prevalent: co-trimoxazole prophylaxis should be initiated regardless of CD4 cell count or WHO stage.</p> <p><i>Conditional recommendation, moderate-certainty evidence</i></p>	<p>Same as children</p>	<p>Regardless of clinical and immune conditions. Priority should be given to all children younger than five years old regardless of CD4 cell count or clinical stage, those with severe or advanced HIV clinical disease (WHO clinical stage 3 or 4) and/or those with CD4 count ≤ 350 cells/mm³.</p> <p><i>Strong recommendation, high-certainty evidence</i></p>	<p>Clinically stable on ART, with evidence of immune recovery and viral suppression.</p> <p><i>Conditional recommendation, low-certainty evidence</i></p> <p>Malaria and/or severe bacterial infections are highly prevalent: co-trimoxazole prophylaxis should be continued regardless of CD4 cell count or WHO clinical stage.</p> <p><i>Conditional recommendation, moderate-certainty evidence</i></p>	<p>Same as children</p>	<p>High prevalence of malaria and/or severe bacterial infections: continued regardless of whether ART is provided.</p> <p><i>Conditional recommendation, moderate-certainty evidence</i></p> <p>Low prevalence of malaria and/or severe bacterial infections: discontinued for children who are clinically stable and/or virally suppressed on ART for at least 6 months and with a CD4 count >350 cells/mm³.</p> <p><i>Strong recommendation, very-low-certainty evidence</i></p>

Intervention	Indication to start			Indication to stop		
	Adults	Adolescents	Children	Adults	Adolescents	Children
Pre-emptive antifungal therapy: fluconazole 800 mg/day for two weeks, then 400 mg/day for eight weeks and continued maintenance with fluconazole 200 mg/day	<p>Blood cryptococcal antigen screening positive among people with CD4 counts <100 cells/mm³ (where lumbar puncture is negative or not feasible or if lumbar puncture excludes cryptococcal meningitis)^a</p> <p><i>Conditional recommendation, low-certainty evidence</i></p>	Same as adults	Not applicable since screening is not recommended	<p>If HIV viral load monitoring is not available: when people are stable and adherent to ART and receiving antifungal maintenance therapy for at least one year and have a CD4 count ≥ 200 cells/mm³ (two measurements six months apart)</p> <p><i>Strong recommendation, low-certainty evidence</i></p> <p>If viral load monitoring is available: when people are stable and adherent to ART and antifungal maintenance treatment for at least one year and have a CD4 cell count ≥ 100 cells/mm³ (two measurements six months apart) and a suppressed viral load</p> <p><i>Conditional recommendation, low-certainty evidence</i></p>	Same as adults ^b	Not applicable since screening is not recommended

^a Everyone with headache or confusion should undergo lumbar puncture.

^b Dosing of fluconazole for adolescents should be reviewed based on weight.

Recommendations (2020)

Identifying populations for latent TB infection testing and TB preventive treatment

People living with HIV

- Adults and adolescents living with HIV who are unlikely to have active TB should receive TB preventive treatment as part of a comprehensive package of HIV care. Treatment should also be given to those receiving ART, to pregnant women and to those who have previously been treated for TB, irrespective of the degree of immunosuppression and even if latent TB infection testing is unavailable (*strong recommendation, high-certainty evidence*).
- Infants aged <12 months living with HIV who are in contact with a person with TB and who are unlikely to have active TB on an appropriate clinical evaluation or according to national guidelines should receive TB preventive treatment (*strong recommendation, moderate-certainty evidence*)

Children aged ≥ 12 months living with HIV who are considered unlikely to have active TB on an appropriate clinical evaluation or according to national guidelines should be offered TB preventive treatment as part of a comprehensive package of HIV prevention and care if they live in a setting with high TB transmission, regardless of contact with a person with TB (*strong recommendation, low-certainty evidence*).

All children living with HIV who have successfully completed treatment for TB disease may receive TB preventive treatment (*conditional recommendation, low-certainty evidence*).

For more information on identifying household contacts (regardless of HIV status) for latent TB infection testing and TB preventive treatment: see WHO consolidated guidelines on tuberculosis: Module 1: prevention: tuberculosis preventive treatment (38).

Algorithms to rule out active TB disease

- Adults and adolescents living with HIV should be screened for TB according to a clinical algorithm. Those who do not report any of the symptoms of current cough, fever, weight loss or night sweats are unlikely to have active TB and should be offered preventive treatment, regardless of their ART status (*strong recommendation, moderate-certainty evidence*).
- Adults and adolescents living with HIV who are screened for TB according to a clinical algorithm and who report any of the symptoms of current cough, fever, weight loss or night sweats may have active TB and should be evaluated for TB and other diseases and offered preventive treatment if active TB is excluded (*strong recommendation, moderate-certainty evidence*).

Chest radiography may be offered to people living with HIV receiving ART and TB preventive treatment given to those with no abnormal radiographic findings (*conditional recommendation, low-certainty evidence*).

Recommendations (2020) (continued)

- **Infants and children living with HIV who have poor weight gain, fever or current cough or who have a history of contact with a person with TB should be evaluated for TB and other diseases that cause such symptoms. If TB disease is excluded after an appropriate clinical evaluation or according to national guidelines, these children should be offered TB preventive treatment, regardless of their age** (*strong recommendation, low-certainty evidence*).
- **The absence of any symptoms of TB and the absence of abnormal chest radiographic findings may be used to rule out active TB disease among HIV-negative household contacts aged ≥ 5 years and other risk groups before TB preventive treatment** (*conditional recommendation, very-low-certainty evidence*).

Testing for latent TB infection

- **Either a tuberculin skin test or interferon-gamma release assay can be used to test for latent TB infection** (*strong recommendation, very-low-certainty evidence*).

TB preventive treatment options

- **The following options are recommended for the treatment of latent TB infection regardless of HIV status: six or nine months of daily isoniazid, or a three-month regimen of weekly rifapentine plus isoniazid, or a three-month regimen of daily isoniazid plus rifampicin** (*strong recommendation, moderate- to high-certainty evidence in the estimates of effect*).
- **A one-month regimen of daily rifapentine plus isoniazid or four months of daily rifampicin alone may also be offered as alternatives** (*conditional recommendation, low- to moderate-certainty evidence*).
- **In settings with high TB transmission, adults and adolescents living with HIV who have an unknown or a positive latent TB infection test and are unlikely to have active TB disease should receive at least 36 months of daily isoniazid preventive therapy. Daily isoniazid preventive therapy for 36 months should be given whether or not the person is receiving ART and irrespective of the degree of immunosuppression, history of previous TB treatment and pregnancy in settings considered to have high TB transmission as defined by national authorities** (*conditional recommendation, low-certainty evidence*).

Source: WHO consolidated guidelines on tuberculosis: Module 1: prevention: tuberculosis preventive treatment (38).

Rationale and evidence

WHO published the recommendation to give TB preventive treatment for all people living with HIV in 2011 (60). A systematic review of 12 randomized controlled trials found that TB preventive treatment reduced the overall risk of TB by 33% (RR 0.67, 95% CI 0.51–0.87) (61).

Pregnancy should not disqualify women living with HIV from receiving preventive treatment with medicines commonly used to treat active TB that are generally considered safe for use in pregnancy, such as isoniazid and rifampicin.

For infants younger than 12 months living with HIV, TB preventive treatment should be given only to those who have a history of household contact with a person with TB and do not have TB disease according to investigations conducted in accordance with national guidelines because of limited data on the benefits (38). TB preventive treatment is strongly recommended for children 12 months or older living with HIV without clinical manifestations suggesting active TB, despite the low certainty of the evidence, because of the clear benefits for adults living with HIV and the high risk of active TB among people living with HIV (38). Children 12 months and older living with HIV who have clinical manifestations or who have contact with a person with TB should be evaluated further and treated for active TB or latent TB infection as indicated. Although the evidence for the efficacy of preventive treatment for children receiving ART is limited, it is biologically plausible given the evidence of additive effects for adults living with HIV receiving ART. Thus, TB preventive treatment is recommended for children living with HIV (38).

Implementation considerations

TB preventive treatment for people living with HIV should be a core component of the HIV package of care and should be primarily the responsibility of national HIV and AIDS programmes and HIV service providers (51). In situations where these tests are not available, TB preventive treatment should not be withheld from eligible people if active disease has been excluded on clinical grounds alone, and chest radiography should not be a requirement for initiating preventive treatment.

Ruling out active TB disease

Excluding active TB disease before initiating preventive treatment is one of the critical steps in the latent TB infection care pathway. For adults and adolescents living with HIV, the four-symptom screen – current cough, fever, weight loss and night sweats – is useful for ruling out active TB, regardless of ART use. *WHO consolidated guidelines on tuberculosis: Module 1: prevention: tuberculosis preventive treatment* (38) includes an algorithm for latent TB infection testing and TB preventive treatment for individuals at risk.

TB preventive treatment options

TB preventive treatment for an infection with strains presumed to be drug-susceptible can be broadly categorized into two types: monotherapy with isoniazid for at least six months (isoniazid preventive therapy) and treatment with regimens containing a rifamycin (rifampicin or rifapentine). Isoniazid preventive therapy has been the most widely used type of TB preventive treatment, but the shorter duration of rifamycin regimens presents a clear advantage (38). Preventive treatment for multidrug-resistant TB requires a different regimen using a fluoroquinolone or other second-line agents (38).

WHO has included both recommendations for regimens containing isoniazid or rifamycins in guidance since 2015 (62). Previous WHO guidance included a strong recommendation for TB preventive treatment alternatives to six months of isoniazid monotherapy based on evidence of low to high certainty. In 2019, WHO made two new conditional recommendations for daily rifapentine plus isoniazid for one month and daily rifampicin monotherapy for four months in all settings. These new recommendations are based on low- to moderate-certainty evidence. In addition, instead of a previous range of 3–4 months, WHO now recommends a duration of three months for daily isoniazid plus rifampicin and of four months of daily rifampicin alone to reflect the usual length of time for which these regimens are currently used.

Moreover, three previous recommendations on using six months of isoniazid monotherapy, three months of daily isoniazid plus rifampicin for people younger than 15 years and daily rifapentine plus isoniazid for three months in high-TB-prevalence settings that featured separately in previous guidance are now proposed as alternative options. The revised recommendation makes all latent TB infection options applicable to all settings (38).

Implementation considerations

The recommendation to give at least 36 months of daily isoniazid monotherapy to people living with HIV in high-TB-transmission settings is conditional and based on evidence that longer-term isoniazid preventive therapy significantly adds benefit to ART. The efficacy, safety and convenience of repeated treatment with shorter rifapentine regimens is being studied among people living with HIV in such settings. WHO defines high-TB-transmission settings as those with a high frequency of individuals with undetected or undiagnosed active TB or in which people with infectious TB are present and there is a high risk of TB transmission, but the national authorities should establish the definition. Testing for latent TB infection is not a prerequisite for TB preventive treatment for people living with HIV, but using it is encouraged because people who are positive on a tuberculin skin test have a greater protective benefit from TB preventive treatment. People living with HIV with a negative tuberculin skin test should not receive 36 months of daily isoniazid preventive therapy.

The benefits of three months of daily isoniazid plus rifampicin for infants and children younger than 15 years outweigh the harm, given its safety profile, the higher rate of completion compared with isoniazid monotherapy and the availability of child-friendly, fixed-dose combinations of rifampicin and isoniazid.

All the treatment options can be self-administered. *WHO consolidated guidelines on tuberculosis: Module 1: prevention: tuberculosis preventive treatment (38)* outlines the recommended dosages of medicines for TB preventive treatment.

Drug–drug interactions

Regimens containing rifamycins should be prescribed with caution to people living with HIV who are receiving ART because of potential drug–drug interactions. These regimens should not be administered to people receiving PIs or NVP, including HIV-exposed infants receiving TB preventive treatment. Rifampicin can decrease the concentrations of ATV, DRV, LPV and other PIs. No dose adjustment is required when rifampicin is co-administered with EFV. The dose of DTG needs to be increased to 50 mg twice daily when given together with rifampicin and twice daily dosing should be continued for an additional two weeks following stop of rifampicin use (63). Results from a recent Phase 1/2 trial of daily rifapentine plus isoniazid for three months and DTG for adults living with HIV reported good tolerability and viral load suppression. However, the Guideline Development Group stressed the continued need for studying the pharmacokinetics of daily rifapentine plus isoniazid for three months concomitantly with other medicines, especially ART.

